CD8A and neoplasm: In a responder of NSCLC patients treated with Pembrolizumab, whole exon sequencing showed that neoantigen-specific CD8+ T-cell responses were parallel to tumor regression, indicating that Anti-PD-1 therapy enhances tumor neoantigen-specific T cell responses (Rizvi et al., 2015).